ERCC2 and non-small cell lung carcinoma: Gurubhagavatula et al (2004) showed that increasing numbers of either XPD or XRCC1 variant alleles and a greater number of variant alleles in combinations of both genes are associated with shorter overall survival after therapy with platinum agents for non-small-cell lung cancer.